N-ACYTYL CYSTEINE AMELIORATES METHOTREXATE INDUCED HEPATIC TOXICITY AND GENOTOXICITY IN MALE ALBINO RATS

Gorge Nazih*** and Walaa Awad***
*Forensic Medicine and Clinical Toxicology department, **Biochemistry department,
Faculty of Medicine, Cairo University and ***Egyptian Fellowship of Clinical Pharmacy.

ABSTRACT

Background: Methotrexate (MTX) is widely used as a cytotoxic chemotherapeutic agent for malignancies as well as in the treatment of various inflammatory diseases. MTX treatment has been associated with hepatic toxicity and genotoxicity. The current study was conducted to assess the potential protective role of N-acetylcysteine in attenuation of methotrexate–induced hepatic damage and genotoxicity in MTX intoxicated male albino rats.

Methods: Forty, apparently healthy adult male albino rats weighed 150±10 gm were randomly divided into four groups; [group 1: negative control group, group 2: positive control (NAC treated) group, group 3: MTX treated group, group 4: MTX/NAC treated group]. The rats were treated once daily for 12 weeks by I.V injection of Methotrexate in a dose of 2 mg/kg (1/7 LD50) and N-acetylcysteine in a dose of 80 mg/kg (1/14 LD50) in the tail veins of rats. Blood samples were obtained at the end of the 4th, 8th and 12th weeks and were prepared for ALT levels and BAX gene expression value examination. At the end of the study, liver samples were obtained for histopathological examination.

Results: A significant constant increase in ALT levels and BAX gene expression value of the MTX-treated group (group 3) was observed throughout the study. Supplementation of NAC concomitantly with MTX in group 4 reduced significantly ALT levels and BAX gene expression value when compared to the non-supplemented group 3 that treated with MTX at the 4th, 8th and 12th weeks (P< 0.000). The previous chemical results were confirmed by the histopathological studies of the liver that revealed the presence of dilatation and congestion of the central veins, hepatic sinusoids, hepatic arteries, portal veins with increased number of Kupffer cells and pyknosis of the hepatic nuclei in group 3: MTX treated group. On the other hand, the liver sections showed the normal hepatic architectures with addition of NAC with MTX in group 4.

Conclusion: The present study showed that NAC has a good protective effect against the hepatic damage and genotoxicity induced by MTX in male albino rats.

INTRODUCTION

Methotrexate was used as part of combination chemotherapy regimens to treat many kinds of cancers. Moreover, it has been used as a treatment for some autoimmune diseases, including Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and scleroderma (Klareskog et al., 2004).

The mechanism of liver injury with methotrexate is believed to be through inhibition of RNA and DNA synthesis in the liver and producing cellular...
arrest. Methotrexate is well known to cause elevations in serum aminotransferase levels, with high dose intravenous methotrexate, serum ALT levels can rise to 10 to 20 times the upper limit of normal (ULN) within 12 to 48 hours, on the other hand, with progress of time levels then fall rapidly to normal with only rare instances of jaundice or symptoms of liver injury. With long term use of low-to-moderate dose methotrexate therapy, elevations in serum ALT or AST values occur in 15 to 50% of patients. Approximately 5% of patients have elevations greater than twice normal and these abnormalities resolve rapidly with discontinuation or dose modification. Furthermore, long term therapy has been linked to development of fatty liver disease, fibrosis and cirrhosis (Reuben, 2007).

Long term therapy with methotrexate has been associated with development of fatty liver, hepatic fibrosis and, in rare instances, portal hypertension, symptomatic cirrhosis and cytogenetic damage. (Chabner et al., 2011).

N-acetyl-cysteine (NAC) is the acetylated form of L-cysteine. It has an impressive list of protective effects including: antioxidant activity, decrease of the biologically effective dose of carcinogens, anti-inflammatory activity, immunological effects, inhibition of progression to malignancy and metastasis, cytogenetic protective effects and protection from the adverse effects of chemopreventive and chemotherapeutic agents. (Sklar and Subramaniam, 2004).

A small pilot study of chronic hepatitis C gave a promise that the addition of NAC to conventional therapy with interferon-α might make the treatment more effective, but a larger multicentre trial in Spain and Italy came to the opposite conclusion (Selzner et al., 2003).

### METHODS

#### Chemicals used:
1. Methotrexate: It is manufactured by PfizerAustralia Pty Ltd. It was given intravenously in tail veins of rats in a daily dose of 2 mg/kg (1/7 LD₅₀).
2. N-acetylcysteine: It is manufactured by American International Chemical, Inc. It was given intravenously in tail veins of rats in a daily dose of 80 mg/kg (1/14 LD₅₀).

#### Animals used & Experimental Design:

Forty, apparently healthy, adult male albino rats (150±10 gm body weight) were obtained from Animal house of Faculty of Medicine-Cairo University. They were housed in hygienic metal cages and kept in a clean well ventilated room. They were fed on standard laboratory diet and allowed free access to water. Rats were left for two weeks before commencement of the study to be acclimatized to lab conditions. All rats were weighed weekly in order to adjust the dose of drugs according to body weight. All doses were given once daily for 12 weeks. Blood samples were obtained at the end of the 4th, 8th and 12th weeks and were prepared for ALT levels and BAX gene expression values examination. By the end of the study; animals’ samples were obtained for liver histopathological examination.

#### Animals were randomly classified into 4 groups:

- **Group 1** (negative control): 10 rats were injected I.V. with 1ml distilled water once daily for 12 weeks.
- **Group 2**: 10 rats were injected I.V. with 1ml Methotrexate (2 mg/kg) daily.
- **Group 3**: 10 rats were injected I.V. with 1ml Methotrexate (2 mg/kg) daily and NAC (80 mg/kg) daily.
- **Group 4**: 10 rats were injected I.V. with 1ml Methotrexate (2 mg/kg) daily and NAC (80 mg/kg) daily.
weeks.

**Group 2** (positive control): 10 rats were supplemented with N-acetylcysteine in dose of 80 mg/kg body weight \((1/14\text{ LD}_{50})\) by intravenous route daily for 12 weeks.

**Group 3**: 10 rats were supplemented with methotrexate in dose of 2 mg/kg body weight \((1/7\text{ LD}_{50})\) by intravenous route daily for 12 weeks.

**Group 4**: 10 rats were supplemented with methotrexate in dose of 2 mg/kg body weight \((1/7\text{ LD}_{50})\) and N-acetylcysteine in dose of 80 mg/kg body weight \((1/14\text{ LD}_{50})\) by intravenous route daily for 12 weeks.

**Biochemical Studies:**

Blood samples were obtained at the end of the 4th, 8th and 12th weeks from the retro-orbital plexus using the capillary pipette method of Halpern and Pacaud, (1951), centrifuged at 1800 r.p.m. and stored in -20 ºC.

An alanine transaminase (ALT) activity is determined according to the method of (Reitman and Frankel, 1957).

DNA damage is determined by studying the Bax gene expression using the Abcam’s Human Baxin vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit.

**Histopathological study:**

Liver samples, obtained at the end of the experiment (the 12th week), were fixed in 10% formalin and processed for paraffin blocks. Sections of 4-5 microns were cut and stained by hematoxylin & eosin according to Bancroft & Stevens, (1977) and examined by light microscope. The sections were viewed and photographed on an Olympus light microscope with attached photograph machine.

**STATISTICAL ANALYSIS:**

Data obtained from the biochemical analysis are represented in tables as Mean ± Standard deviation (mean ± SD). The One-Way ANOVA test was used for statistical analysis of data. The analysis was done using the SPSS-PC computer software package version 10 Abacus Concepts (1989).

**RESULTS**

No difference was observed between the negative and positive control groups concerning the ALT levels.

At the end of the fourth week, the ALT level of the Methotrexate-treated group (group 3) increased about 3.46 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine (group 4), the ALT level decreased significantly about 11.88% as compared to that of the Methotrexate-treated group, but still 3 times higher than that of the negative control group (P< 0.000). At the end of the eighth week, the ALT level of the Methotrexate-treated group (group 3) increased about 3.68 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine-treated group (group 4), the ALT level decreased significantly about 23.3% as compared to that of the Methotrexate-treated group, but still 2.82 times higher than that of the negative control group (P< 0.000). At the end of the twelve weeks, the ALT level of the Methotrexate-treated group increased about 3.76 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine (group 4), the ALT level decreased significantly by 34.7% as compared to
that of the Methotrexate-treated group (group 5), but still it was about 2.45 times higher than that of the negative control group (P< 0.000).

A significant constant increase of the ALT level of the Methotrexate-treated group (group 3) was observed throughout the study. The level increased about 5% at the end of 8th week and became about 10.4% more at the end of 12th week as compared to its similarity of the 4th week. In the N-acetylcysteine-treated group (group 4), the ALT level decreased about 8.6% at the end of 8th week and became about 18% less at the end of 12th week as compared to its similarity of the 4th week-treated group (Table 1).

No difference was observed between the negative and positive control groups concerning the BAX levels.

At the end of the fourth week, the BAX level of the Methotrexate-treated group (group 3) increased about 6.5 times than that of the negative control group (P< 0.000). In the N-acetylcysteine-treated group (group 4), the BAX level decreased significantly about 23.1% as compared to that of the Methotrexate-treated group, but still it was about 5 times higher than that of the negative control group (P< 0.000). At the end of the eighth week, the BAX level of the Methotrexate-treated group (group 3) increased about 9.16 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine (group 4), the BAX level decreased significantly about 45.45% as compared to that of the Methotrexate-treated group, but it was 3.57 times higher than that of the negative control group (P< 0.000). A significant constant increase in the level of BAX of the Methotrexate-treated group (group 3) was observed throughout the study. The level increased about 20.8% at the end of 8th weekend became about 48.3% more at the end of 12th week as compared to its similarity of the 4th week.

In the N-acetylcysteine-treated group (group 4), the BAX decreased about 14.2% at the end of 8th week and became about 28.5% less at the end of 12th week as compared to its similarity of the 4th week-treated group (Table 2). The histological sections of the liver of the negative control group (Figure 1) and positive control group (Figure 2) were normal.

The histological sections of the liver of the Methotrexate-treated rats (group 3) showed the presence of dilatation and congestion of the central veins, hepatic sinusoids, hepatic arteries and portal veins. The increased number of Kupffer cells and pyknosis of the hepatic nuclei was characteristic features of this group (Figures 3&4). The liver sections of N-acetylcysteine-Methotrexate treated group (group 4) showed dilated and congested hepatic sinusoids with better histopathological appearance than group 3 (Figure 5).
**Table (1):** Shows ANOVA one-way statistical analysis of the ALT levels (IU/L) in all studied groups throughout the experimental period in rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>ALT levels (IU/L)(mean±SD)</th>
<th>4&lt;sup&gt;th&lt;/sup&gt; week</th>
<th>8&lt;sup&gt;th&lt;/sup&gt; week</th>
<th>12&lt;sup&gt;th&lt;/sup&gt; week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>26.07±5.6* cd</td>
<td>25.77±6.82* cd</td>
<td>26.54±8.32* cd</td>
<td></td>
</tr>
<tr>
<td>Group 2</td>
<td>27.03±5.64* cd</td>
<td>26.33±5.57* cd</td>
<td>26.75±7.77* cd</td>
<td></td>
</tr>
<tr>
<td>Group 3</td>
<td>90.40±15.39* abd</td>
<td>94.95±15.86* abd</td>
<td>99.85±16.64* abd</td>
<td></td>
</tr>
<tr>
<td>Group 4</td>
<td>79.66±9.70* abc</td>
<td>72.77±12.31* abc</td>
<td>65.17±11.96* abc</td>
<td></td>
</tr>
</tbody>
</table>

* = statistical significant difference at p ≤ 0.05  

a = significant difference versus group 1  
b = significant difference versus group 2  
c = significant difference versus group 3  
d = significant difference versus group 4  

**Group 1 =** Negative control.  
**Group 2 =** Rats received doses equal to 1/14 of LD<sub>50</sub> of N-acetylcysteine.  
**Group 3 =** Rats received doses equal to 1/7 of LD<sub>50</sub> of methotrexate.  
**Group 4 =** Rats received doses equal to 1/7 of LD<sub>50</sub> of methotrexate & 1/14 of LD<sub>50</sub> of N-acetylcysteine.

**Table (2):** Shows ANOVA one-way statistical analysis of the BAX Gene expression values in all studied groups throughout the experimental period in rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>BAX gene (mean±SD)</th>
<th>4&lt;sup&gt;th&lt;/sup&gt; week</th>
<th>8&lt;sup&gt;th&lt;/sup&gt; week</th>
<th>12&lt;sup&gt;th&lt;/sup&gt; week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>0.14±0.01* cd</td>
<td>0.12±0.01* cd</td>
<td>0.14±0.01* cd</td>
<td></td>
</tr>
<tr>
<td>Group 2</td>
<td>0.13±0.01* cd</td>
<td>0.13±0.01* cd</td>
<td>0.13±0.01* cd</td>
<td></td>
</tr>
<tr>
<td>Group 3</td>
<td>0.91±0.27* abd</td>
<td>1.10±0.29* abd</td>
<td>1.34±0.34* abd</td>
<td></td>
</tr>
<tr>
<td>Group 4</td>
<td>0.70±0.16* abc</td>
<td>0.60±0.16* abc</td>
<td>0.50±0.16* abc</td>
<td></td>
</tr>
</tbody>
</table>

* = statistical significant difference at p ≤ 0.05  

a = significant difference versus group 1  
b = significant difference versus group 2  
c = significant difference versus group 3  
d = significant difference versus group 4  

**Group 1 =** Negative control.  
**Group 2 =** Rats received doses equal to 1/14 of LD<sub>50</sub> of N-acetylcysteine.  
**Group 3 =** Rats received doses equal to 1/7 of LD<sub>50</sub> of methotrexate.  
**Group 4 =** Rats received doses equal to 1/7 of LD<sub>50</sub> of methotrexate & 1/14 of LD<sub>50</sub> of N-acetylcysteine.
Figure (1): Photomicrograph of a cross section in the liver of a rat of the negative control group (group 1) showing normal hepatic sinusoid (S) near the central vein (CV) (H&E x 400).

Figure (2): Photomicrograph of a cross section in the liver of a rat of the positive control group (group 2) showing normal hepatic sinusoid (S) near the bile duct (BD) (H&E x 400).

Figure (3): Photomicrograph of a cross section in the liver of a rat of the Methotrexate-treated group (group 3) showing a dilated congested hepatic artery and portal vein (PV). Pyknosis of hepatic nuclei (arrowheads) with increased number of Kupffer cells (arrows) are seen. Not bile duct (BD) (H&E x 400).
Figure (4): Photomicrograph of a cross section in the liver of a rat of the Methotrexate-treated group (group 3) showing a hugely dilated congested portal vein (PV) and dilated congested sinusoids (S) near the bile duct (BD) (H&E x 400).

Figure (5): Photomicrograph of a cross section in the liver of a rat of the N-acetylcysteine- Methotrexate treated group (group 4) showing dilated and congested hepatic sinusoids (S). Note Kupffer calls (arrows) and binucleated hepatic cells (B) (H&E x 400).

DISCUSSION

The purpose of this study was to test the protective effect of N-acetyl cysteine on Methotrexate induced hepatic toxicity in albino rats.

In the current study, the ALT levels of the methotrexate-treated group (group 3) increased about 3.46, 3.68 and 3.76 times than that of the negative control group at the end of the 4th, 8th and 12th weeks of the study respectively (P< 0.000). 

Aithal, 2011 reported that with high dose intravenous MTX; serum ALT levels can rise to 10 to 20 times the upper limit of normal within 12 to 48 hours.

Similar results were recorded by Aithal, 2011 who reported that with long term MTX therapy, elevations in serum ALT values occurred in 15 to 50% of patient. In addition, Van Ede et al., 2001 concluded that methotrexate (MTX) can induce elevation of serum transaminases.
The previous biochemical findings that reflect deteriorated liver functions were confirmed by the corresponding hepatic cellular changes. The most characteristic feature of the examined hepatic sections of rats treated with MTX (group 3) in the current study was the presence of massive dilatation and congestion of central veins, hepatic sinusoids, portal veins and hepatic arteries.

The use of the N-acetylcysteine in addition to MTX in group 4 resulted in significantly decreased ALT levels at the end of the 4th, 8th and 12th weeks by 11.88%, 23.3% and 34.7% respectively as compared to that of the methotrexate-treated group (P< 0.000). Meanwhile, the liver sections of N-acetylcysteine-MTX treated rats (group 4) showed the normal hepatic architectures with nearly normal hepatic sinusoids and normal central veins. Cetinkaya et al., 2006 stated that N-acetylcysteine (NAC) is a well-established cytoprotective drug that has proven efficacy against drug (acetaminophen overdose)-induced hepatotoxicity (Cetinkaya et al., 2006).

BAX is a member of the Bcl-2 gene family. BCL2 family members form hetero- or homodimers and act as markers of apoptosis which indicates DNA damage (Rekha and Selvakumar, 2014).

In the current study, the BAX gene expression value was used as a marker for genotoxic damage. In the methotrexate-treated rats (group 3), the BAX gene expression values showed a significant progressive increase in its values throughout the study in relation to the negative control group (P< 0.000). These results go hand in hand with those of Criswell et al., 2003 who reported that MTX could induce increased frequencies of micronuclei and chromosomal aberrations in both rats and humans. Keshava et al., 1998 reported that MTX could induce a significant increase in percent of micronucleated and binucleated cells and percent of aberrant cells in V79 cells of Chinese hamster lung fibroblast cells which have been widely used in studies of DNA damage and DNA repair.

In the present study, with the addition of NAC to MTX in group 4, the Bax gene expression values significantly decreased 23.1%, 45.45% and 62.6% at the 4th, 8th and 12th weeks respectively as compared to that of the methotrexate-treated rats (group 3), but it was still about 5.92, 5 and 3.57 times higher than that of the negative control group at the end of the 4th, 8th and 12th weeks respectively. These results were similar to those recorded by Reliene et al., 2004 who concluded that the antioxidant NAC counteracted the oxidative DNA damage induced by MTX.

Farombi, 2006 reported that N-acetylcysteine has been shown to be an antigentotoxic agent, exhibiting protective effects against DNA oxidative damage by its antioxidant property. Balansky and Flora 2004 reported that NAC may decrease cytogenetical damage produced by exposure to cigarette smoke and mutagenic agents as urethane and 2-acetylaminofluorene in rodents, suggesting chemopreventive effects.

In conclusion, the current study showed that NAC has a good protective effect against the hepatic damage and genotoxicity induced by MTX in rats. So it may be useful to use NAC as an adjunctive supplementation to alleviate
the hepatic damage and genotoxicity induced by MTX in rats.

In the view of the present study, we recommend to conduct the same study on human beings in order to investigate the feasibility and suitability of the results of the present study on human beings.

REFERENCES


Said et al.

Interact, 217: 57-66.


التأثير الوظيفي لن استيبل سيسترين على التسمم الكدي والهكسين الجيني المحدث

وسادة الميثودوكسيت في ذكور الفئران البيضاء

*هالة عبد، أماني صالح، علاء شهاب، أحمد الشعثوي، آمنة الخولى*، جورج نزه

ولاء عوض

قسم الطب الشرعي والسوموم الإكلينيكية وقسم الكيمياء الحيوية -كلية الطب جامعة القاهرة

الرملة المصرية-الصناديق الإكلينيكية

**

يشتخدم عقار الميثودوكسيت على نطاق واسع في علاج الأورام الخبيثة وكثير من الأمراض الالتهابية

والترابط مع العلاج بالميثودوكسيت في التسمم الكدي والهكسين الجيني

وتحدد هذه الدراسة إلى دراسة الأثر الوظيفي لن استيبل سيسترين على التسمم الكدي والهكسين الجيني

ويجري الدراسة على أربعين من ذكور الفئران البيضاء البالغة التي تزن حوالي 150 جرام تم الحصول

على أربعة مجموعات ممنوعة المجموعة الأولى: المجموعة الضاغطة السلبية وشملت عشرة فئران

الثاني: مجموعة الميثودوكسيت وشملت عشرة فئران

الثالث: مجموعة الفئران المجموعة الرابعة: مجموعة

ن استيبل سيسترين مع الميثودوكسيت وشملت عشرة فئران وتمت إعاثاتهم في أقفاز معدنية في حجرة

الثاني والثاني عشر لتقديم طفايت الكبد والسمية الجنسية عند نهاية الأسبوع الرابع والثامن

الثاني عشر لتقديم طفايت الكبد والسمية الجنسية عند نهاية الدراسة تم تشريح الفئران للحصول على عينات

نسيجية كبدية لإجراء الدراسات النسبية الباثولوجية

وأخيراً تظهر زيادة مطردة في مستويات إنزيمات تسترنز في المجموعة الثالثة التي

حققت بالميثودوكسيت مقابلة بالمجموعة الضاغطة السلبية عند الأسبوع الرابع والثامن والثاني عشر من

الدراسة. وعند إضافة ن استيبل سيسترين مع الميثودوكسيت في المجموعة الرابعة لوحظ انخفاض محذور في

قيمة إنزيمات تسترنز مقارنة بالمجموعة الثالثة

بالنسبة لقيمة التعبير عن الباكس جين ارتفعت زيادة ثابتة في قيمة التعبير عن الباكس جين في مجموعة

الميثودوكسيت المجموعة الثالثة مقارنة بالمجموعة الضاغطة السلبية عند الأسبوع الرابع والثامن والثاني عشر

من الدراسة. وعند إضافة ن استيبل سيسترين مع الميثودوكسيت في المجموعة الرابعة لوحظ انخفاض صغير في

الخلايا كافٍ لتفريق نواتياً الإكلينيقية في المجموعة الثانية: المجموعة الميثودوكسيت

ولقد تم تأكيك هذه التغييرات الكيميائية الخاصة بإبادة الأين تسترنز بطرق الدراسات السريرية للدكت

وقبل أن تظهرت اتساع واحتكان الأوردة الكبدية المركزية والشرايين الكبدية والأوردة الكبدية البالبية وزيادة في عدد

الخلايا كافٍ لتفريق نواتياً الإكلينيقية في المجموعة الثانية: المجموعة الميثودوكسيت. وعند العكس من

ذلك أوضحت الدراسات السريرية الكبدية عند إضافة ن استيبل سيسترين في المجموعة

الرابعة تحسن بشكل نسبي لكبدية مقارنة بالمجموعة الثالثة

وخلصت الدراسة إلى أن تعاطي ن استيبل سيسترين بالتزامن مع الميثودوكسيت قد ادى إلى تحسن ملحوظ

في وظائف الكبد وانخفاض في معدل التعبير عن جين باكس وأدى كذلك إلى تحسن في التغيرات الباثولوجية في

الكبد ووصفي الدراسة بتعاطي ن استيبل سيسترين في المرضى الذين يعانون من العلاج بالميثودوكسيت لتفعيل

سيمته الكبدية والجينية

Said et al.